# Long-acting growth hormone for pediatric GHD: insights into molecular modification and clinical application

## TL;DR

This review explores long-acting growth hormone therapies for children with growth hormone deficiency, focusing on their development, effectiveness, and future needs.

## Contribution

The paper offers a comprehensive evaluation of LAGH therapies, integrating clinical data and international consensus for practical clinical guidance.

## Key findings

- LAGH therapies reduce the need for daily injections in GHD treatment.
- Molecular engineering strategies have successfully extended the half-life of growth hormone.
- The review highlights gaps in real-world evidence and the need for further research.

## Abstract

Long-acting growth hormone (LAGH) therapies represent a paradigm shift in the management of growth hormone deficiency (GHD), alleviating the burden of daily injections. This review comprehensively evaluates the LAGH landscape, detailing molecular engineering strategies that extend half-life, and assessing the pharmacokinetics, efficacy, and safety of globally approved agents and candidates in China. By integrating pivotal trial data with recent international consensus, we provide a practical framework for clinical management, including patient selection and monitoring. Furthermore, we identify critical knowledge gaps in the field, highlight the need for high-quality real-world evidence, and explore promising future directions. This review thereby provides a holistic perspective on the current progress and unmet needs in LAGH therapy.